Visual outcomes of photorefractive keratectomy in non-children with anisometropic amblyopia: One-year Follow-up Outcomes

医学 眼科 光折变性角膜切除术 立体视敏度 屈光参差 验光服务 折射误差 视力
作者
Mohammad Etezad-Razavi,Bahar Tafaghodi-Yousefi,Alireza Eslampour,Mohammad Yaser Kiarudi,Marzieh Najjaran,Hamed Momeni‐Moghaddam,Jorge L. Alió
出处
期刊:European Journal of Ophthalmology [SAGE Publishing]
卷期号:32 (5): 2615-2621 被引量:1
标识
DOI:10.1177/11206721211073033
摘要

Objective To evaluate the safety, efficiency, short term stability, and sensory results of photorefractive keratectomy (PRK) in anisometropic in non-compliant children with correction. Methods Twelve eyes of 12 children with an age range: 6–17 years and anisometropic amblyopia who underwent PRK under general anesthesia to correct the dioptric difference between the eyes were included in this study. A complete ophthalmic assessment including refractive status, uncorrected and corrected distance visual acuity (UDVA & CDVA), and binocular vision status using the Worth 4-dot test and stereopsis were performed before and 1, 3, 6, and 12 months after PRK. Results The mean preoperative CDVA was 0.34 ± 0.24 LogMAR which showed a statistically significant improvement at 12 months (0.20 ± 0.19, p = 0.024) after surgery compared to the preoperative assessment. (p = 0.003) The mean preoperative UDVA was 0.63 ± 0.24 LogMAR that increased to 0.44 ± 0.24, 0.32 ± 0.16, 0.25 ± 0.19, and 0.25 ± 0.19 LogMAR at 1, 3, 6, and 12 months after PRK, respectively. One to three lines improvement in UDVA and CDVA was seen in 10 (83.4%) and 8 eyes (66.7%); while one line UDVA and CDVA loss was seen in one (8.3%) and one (8.3%) eye and unchanged UDVA and CDVA was seen in 1 (8.3%) and 3 eyes (25%), respectively. The mean preoperative stereoacuity was 341.9 ± 245.7 s of arc, which significantly improved to 166.6 ± 87.5 s of arc 12 months after PRK. (p = 0.012) Conclusion PRK was an effective surgical alternative to improve visual acuity and stereopsis in anisometropic children who did not cooperate with conventional methods of amblyopia therapy.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
红朱古力酒完成签到 ,获得积分10
1秒前
leilei完成签到 ,获得积分10
1秒前
1秒前
2秒前
爱岗敬业牛马人完成签到,获得积分10
2秒前
科研通AI6.3应助haha采纳,获得10
2秒前
六沉完成签到 ,获得积分10
4秒前
RaeganWehe完成签到,获得积分20
6秒前
达到毕业要求了吗完成签到 ,获得积分10
6秒前
殷勤的紫槐给neu_zxy1991的求助进行了留言
6秒前
simongao完成签到 ,获得积分10
6秒前
6秒前
破罐子完成签到 ,获得积分10
7秒前
络桵发布了新的文献求助10
7秒前
jiao完成签到,获得积分10
8秒前
Ayn完成签到 ,获得积分10
8秒前
生已踽踽完成签到,获得积分10
9秒前
动点子智慧完成签到,获得积分10
10秒前
重要板凳完成签到 ,获得积分10
10秒前
11秒前
贪玩绮南完成签到 ,获得积分10
12秒前
lzqlzqlzqlzqlzq完成签到,获得积分10
14秒前
香蕉秋蝶完成签到 ,获得积分10
14秒前
小白一枚完成签到 ,获得积分10
15秒前
15秒前
破罐子关注了科研通微信公众号
15秒前
MadysonKotrba完成签到,获得积分20
15秒前
WY完成签到,获得积分10
15秒前
假装超人会飞完成签到,获得积分10
16秒前
hajimi完成签到,获得积分10
17秒前
17秒前
科研通AI2S应助雨洋采纳,获得100
17秒前
傲娇的秋莲完成签到,获得积分10
18秒前
18746005898完成签到 ,获得积分10
18秒前
平常莹芝完成签到,获得积分0
19秒前
小李叭叭完成签到,获得积分10
20秒前
冷傲鸡翅完成签到,获得积分10
20秒前
dawd12完成签到,获得积分10
22秒前
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Picture this! Including first nations fiction picture books in school library collections 1000
Signals, Systems, and Signal Processing 610
Unlocking Chemical Thinking: Reimagining Chemistry Teaching and Learning 555
Photodetectors: From Ultraviolet to Infrared 500
Cancer Targets: Novel Therapies and Emerging Research Directions (Part 1) 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6359032
求助须知:如何正确求助?哪些是违规求助? 8173021
关于积分的说明 17212158
捐赠科研通 5414033
什么是DOI,文献DOI怎么找? 2865350
邀请新用户注册赠送积分活动 1842737
关于科研通互助平台的介绍 1690871